SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001867096-21-000053
Filing Date
2021-10-05
Accepted
2021-10-05 17:18:12
Documents
2
Period of Report
2021-10-05

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_163346866327386.html 3  
1 FORM 3 wf-form3_163346866327386.xml 3 1819
2 JOHNSON, KENNETH ERLAND POA ex-24.htm EX-24 3020
  Complete submission text file 0001867096-21-000053.txt   6247
Mailing Address C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1800 CHICAGO IL 60601
Business Address
JOHNSON KENNETH ERLAND (Reporting) CIK: 0001743774 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40880 | Film No.: 211307726

Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations